Tremelimumab-associated tumor regression following after initial progression: two case reports
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tremelimumab-associated tumor regression following after initial progression: two case reports
Authors
Keywords
-
Journal
Immunotherapy
Volume 8, Issue 1, Pages 9-15
Publisher
Future Medicine Ltd
Online
2015-10-02
DOI
10.2217/imt.15.89
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study
- (2015) Luana Calabrò et al. Lancet Respiratory Medicine
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
- (2012) Sofie Wilgenhof et al. CANCER INVESTIGATION
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
- (2011) Douglas G. McNeel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma
- (2011) Michele Del Vecchio et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
- (2010) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started